[Form 3] BioLineRx Ltd. Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
BioLineRx Ltd. director Aharon Schwartz filed an initial ownership report showing direct holdings of 3,705,000 Ordinary Shares. He also holds multiple fully vested and time-vested employee stock options under the company’s 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.92 per share and expirations extending through 2034. A large October 2024 grant covers 2,055,000 underlying Ordinary Shares, of which 856,200 were vested at appointment and the remaining 1,198,800 are scheduled to vest in seven equal quarterly installments, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Schwartz Aharon
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares, 0.1 NIS per share | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 49,800 shares (Direct);
Ordinary Shares, 0.1 NIS per share — 3,705,000 shares (Direct)
Footnotes (1)
- Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.
Key Figures
Ordinary Shares held: 3,705,000 shares
Option exercise price: $0.8370 per share
Option exercise price: $0.9200 per share
+5 more
8 metrics
Ordinary Shares held
3,705,000 shares
Directly held Ordinary Shares as of Form 3
Option exercise price
$0.8370 per share
Employee Stock Option expiring July 5, 2026
Option exercise price
$0.9200 per share
Employee Stock Option expiring July 5, 2027
Large 2019 option grant
199,800 underlying shares at $0.3560
Option expiring July 2, 2029
Large 2022 option grant
1,080,000 underlying shares at $0.0850
Option expiring July 3, 2032
October 2024 option grant
2,055,000 underlying shares at $0.0520
Option expiring August 14, 2034
Vested portion of 2024 grant
856,200 options
Vested as of appointment date October 1, 2024
Unvested portion of 2024 grant
1,198,800 options
To vest in seven equal quarterly installments
Key Terms
Employee Stock Option (Right to Buy), 2003 Amended and Restated Share Incentive Plan, Section 102 of the Israeli Tax Ordinance, Ordinary Shares, +2 more
6 terms
Employee Stock Option (Right to Buy) financial
"security_title: "Employee Stock Option (Right to Buy)""
Section 102 of the Israeli Tax Ordinance financial
"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance"
fully vested financial
"This option grant is fully vested as of this date."
trustee financial
"securities issued to an employee ... must be registered in the name of a trustee"
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
FAQ
What does the BioLineRx (BLRX) Form 3 filing by Aharon Schwartz show?
The Form 3 shows director Aharon Schwartz’s initial holdings in BioLineRx, including 3,705,000 Ordinary Shares and several employee stock option grants with various exercise prices and expiration dates under the company’s 2003 Amended and Restated Share Incentive Plan.
What stock option grants are reported for Aharon Schwartz in BioLineRx (BLRX)?
The filing lists multiple Employee Stock Option (Right to Buy) grants over several years, with exercise prices between $0.052 and $0.92 per share. Each grant is tied to specific expiration dates extending from 2026 through 2034, covering defined numbers of underlying Ordinary Shares.
What is notable about the October 2024 BioLineRx (BLRX) option grant to Aharon Schwartz?
The October 2024 grant covers 2,055,000 underlying Ordinary Shares at a $0.052 exercise price. Footnotes state 856,200 options were vested at appointment and the remaining 1,198,800 options vest in seven equal quarterly installments, subject to continued service.
Under which plan were Aharon Schwartz’s BioLineRx (BLRX) options granted?
Footnotes state options were granted under the 2003 Amended and Restated Share Incentive Plan. To qualify for tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with this plan must be registered in the name of a trustee.
Are Aharon Schwartz’s BioLineRx (BLRX) options vested or subject to vesting?
Several option grants are described as fully vested as of their grant dates between 2016 and 2024. The large October 2024 grant is partially vested, with 1,198,800 options scheduled to vest in seven equal quarterly installments if he continues serving the company.